Clinical Development & Data
Trial architecture, endpoints, recruitment, investigator interpretation, small-population evidence, comparators, and the way clinical signals will be read downstream.
Rare Disease & Genetic Medicines
ICG works across rare-disease and genetic-medicine environments where clinical evidence, manufacturing readiness, regulatory interpretation, access architecture, field organization, and treatment delivery must be read as one decision system.
The work includes rare disease competitive intelligence, clinical and regulatory strategy, manufacturing and CMC assessment, market-access and launch analysis, field-force and patient-system evaluation, and longitudinal company-side evidence development.
One Field. Multiple Commitment Systems.
Rare disease is not treated here as a narrow therapeutic label. An asset may depend simultaneously on trial design, small-population evidence, manufacturing reproducibility, diagnostic access, center readiness, reimbursement, patient identification, delivery infrastructure, and company-side commitment.
ICG reconstructs how those conditions interact before they are separated into clinical, regulatory, access, commercial, manufacturing, or organizational workstreams. The purpose is not to add another layer of information, but to identify which relationships govern the decision field.
Decision Environments
Engagements begin at different points, but the governing constraints often cross the boundaries of the initial request.
Manufacturing & CMC Readiness
Capacity, potency, comparability, supply, vial and dose configuration, partner readiness, and the relationship between manufacturing uncertainty and asset value.
Regulatory & Access Pathways
Filing logic, label conditions, evidence requirements, reimbursement, affordability, testing access, treatment-center readiness, and country-level adoption constraints.
Launch & Commercial Architecture
Market preparation, account and center coverage, field-force design, KAM and MSL roles, patient services, distribution, channel structure, and launch sequencing.
Patient & Treatment Systems
Patient finding, diagnostic pathways, referral patterns, centers of excellence, administration burden, monitoring, support programs, and continuity of treatment.
Longitudinal Competitive Monitoring
Clinical, regulatory, manufacturing, access, organization, and commercial signals reconstructed across multi-phase and multi-year asset or portfolio programs.
Evidence Architecture
The evidence base is developed through source calls and interviews positioned close to the decisions, constraints, and operating conditions being reconstructed.
Clinical & Investigator Side
Key opinion leaders, principal investigators, study-site personnel, treating specialists, centers of excellence, diagnostic pathways, and investigator-side clinical teams.
Company-Side Sources
Clinical development, regulatory, medical affairs, CMC and manufacturing, market access, patient services, field leadership, commercial, and portfolio functions.
Access & Treatment Systems
Payer and reimbursement environments, specialty distribution, treatment centers, testing providers, administration systems, patient-support infrastructure, and local access pathways.
Triangulation
Interview evidence is tested against clinical, regulatory, manufacturing, access, and organizational signals and against the criteria used by reviewers, payers, clinicians, partners, and other decision-makers.
Selected Project Record
Selected engagements across rare disease and genetic medicines.
The projects below are selected from a substantially larger body of work. They were chosen to illustrate different decision environments, lifecycle stages, modalities, geographies, and forms of engagement. The selection is illustrative rather than exhaustive. Multi-phase and longitudinal assignments may be presented as a single project title, and company, asset, or market details may be generalized where appropriate.
Clinical Development & Data
- Clinical-Development Landscape for Gene Therapies in Pompe Disease
- Clinical and Commercial Assessment of an RNAi Therapy in Transthyretin Amyloidosis
- Clinical-Development and Endpoint Assessment for Gene Therapies in Rett Syndrome
- Competitive Development Monitoring in Fragile X Syndrome
- Clinical-Data Interpretation for In Vivo Gene-Editing Therapies in Hereditary Angioedema
- Trial-Design and Recruitment Assessment Across Hemophilia and Rare Blood Disorders
Manufacturing, CMC & Delivery
- Manufacturing, Potency-Testing and Commercial-Readiness Assessment for a Duchenne Muscular Dystrophy Gene Therapy
- Manufacturing-Capacity and Site-Readiness Assessment for Neuromuscular Gene Therapies
- Device, Manufacturing and Partner Landscape for Hemophilia Gene Therapy
- Delivery-System and Administration Architecture for Rare-Disease Biologics
- Vial-Size, Potency and Supply Architecture for a Rare-Disease Gene Therapy
- CMC and Regulatory Readiness for a Subcutaneous Rare-Disease Therapy
Regulatory, Access & Adoption
- Market-Access and Uptake Assessment of Gene Therapies in Developed and Emerging Markets
- Reimbursement and Launch Architecture for a Gene Therapy in Metachromatic Leukodystrophy in Europe
- Treatment-Center Adoption of a Gene Therapy for Hemophilia B in the United States
- Access and Affordability Architecture for Rare-Disease Therapies in Emerging Markets
- Genetic-Testing Access and Adoption in Rare Disease
- Regulatory and Adoption Pathway for a Complement-Inhibitor Therapy in PNH in China
Launch & Commercial Architecture
- Commercial and Launch Architecture for a Gene Therapy in Spinal Muscular Atrophy
- Field-Force Benchmarking for Hemophilia Therapies in Europe
- Clinical, Market-Access and Commercialization Assessment for Therapies in Sickle Cell Disease and Related Hemoglobinopathies
- Launch and Field-Organization Assessment for Hereditary Angioedema Therapies in the United States and Europe
- Commercial and Patient-System Architecture for Hunter Syndrome Therapies Across Selected International Markets
- Field Resourcing, Patient Support and Market-Access Architecture for a Rare Endocrine Therapy in Europe
Longitudinal Monitoring & Portfolio
- Global Hemophilia Benchmarking Across Clinical Development, Field Force and Delivery Devices
- Hemophilia Gene-Therapy Monitoring Across Clinical and Commercial Development
- Longitudinal Competitive Monitoring of Hunter Syndrome Therapies Across Multiple Markets
- Portfolio and Pipeline Monitoring for Rare Disease and Genetic Medicines in Emerging Markets
- Competitive Monitoring of Complement Therapies in PNH and Hereditary Angioedema
- Multi-Year Launch, Access and Field-Organization Monitoring Across Rare-Disease Portfolios
Rare Disease Engagements
ICG can enter at the level of a single critical question, a multi-market evidence program, or a longitudinal clinical, regulatory, manufacturing, access, or commercial decision environment.